Scientists discover potential new treatment for a deadly tick-borne illness

Key Points:

• Researchers have identified specially designed antibodies, particularly AG028, that show potential in reducing allergic reactions linked to alpha-gal syndrome (AGS), a serious allergy triggered by tick bites.
• AG028 demonstrated the ability to reduce basophil activation by up to 86% in laboratory tests, although it did not completely prevent allergic reactions, indicating the need for further research.
• The study involved isolating 42 human antibodies from individuals exposed to malaria, with 13 showing binding to alpha-gal allergens, and two antibodies (AG028 and AG050) capable of blocking IgE binding.
• AGS is caused by the immune system reacting to alpha-gal transferred into the bloodstream via tick bites, commonly from the lone star tick in the U.S., leading to allergic responses after consuming red meat or related products.
• While the antibody treatment remains experimental and has not yet been tested in patients, the findings represent a promising step toward developing new therapies for this potentially life-threatening tick-borne condition.